Presentación    
CANCER MOLECULAR PATHOLOGY
AND THERAPEUTIC TARGETS

 
 
Composition
Name
Position
Institution
David Hardisson Hernáez
Jefe de Servicio de Anatomía Patológica
Profesor Titular. Facultad de Medicina
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Alberto Berjón García
Médico Adjunto Especialista de Área en Anatomía Patológica
Hospital Universitario La Paz
Emilio Burgos Lizáldez
Facultativo Especialista de Área en Anatomía Patológica
Hospital Universitario La Paz
Javier de Santiago García
Jefe de Servicio de Ginecológica Oncológica Profesor Asociado. Facultad de Medicina
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Laura Guerra Pastrián
Médico Adjunto Especialista de Área en Anatomía Patológica
Hospital Universitario La Paz
Jorge Martín Pérez
Investigador Científico
IIB "Alberto Sols"
Marta Mendiola Sabio
Investigadora Postdoctoral
 
Hospital Universitario La Paz
María Miguel Martín
Técnico de Laboratorio
Hospital Universitario La Paz
Alberto Peláez
García
Investigador Postdoctoral
Hospital Universitario La Paz
Elia Pérez Fernández
Investigadora Predoctoral
Hospital Universitario La Paz
José Juan Pozo Kreilinger
Facultativo Especialista de Área en Anatomía Patológica
Hospital Universitario La Paz
José Ignacio Sánchez Méndez
Facultativo Especialista de Área en Ginecología y
Obstetricia
Profesor Asociado. Facultad de Medicina
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Laura Yébenes Gregorio
Médico Adjunto Especialista de Área en Anatomía Patológica
Hospital Universitario La Paz
Strategic Objective
The fundamental interest of our research group is centered in the study of molecular biomarkers that have a direct implication in the handling of the cancer patients with the last aim to identify and to validate therapeutic targets.
 
Ovarian cancer Research Line
The ovarian carcinoma is the main cause of gynecological cancer mortality in the western societies.
Nevertheless, the classic parameters are imperfect predictors for patients outcome, partly due to the complexity of the molecular genetic events that sublie these tumors and to the fact that they are not totally known. Research on this field could identify more precise markers to correctly stratify the patients according to their probability to recur and response to treatments.
Angiogenesis, epithelial to mesenchymal transition and hypoxia are processes demonstrated to have an important role in the development of these tumors.
The main objective of this line of investigation, therefore, is to identify discrete markers or gene expression profiles related to these events, with value predictive and prognostic value for ovarian cancer patients.
 
Breast cancer Research Line
• C-Src is sobreexpressed and/or hyperactive in breast carcinoma biopsies and their implication in the tumorigenesis has been proved in murine models.
Our studies on genetically modified human breast cancer cells and mice can establish the relevance of the function of scaffolding of SFKs in breast cancer. In addition, our work can lead to the development of new prognosis and therapeutic tools to improve the treatment of the breast cancer.
• Angiogenesis and cancer of breast. The angiogenesis is a key process in tumor development. Our group has been working for years on the search of biomarkers related to this process. Specifically on breast cancer, it is important to identify patients that will benefit of bevacizumab containing regimes.
 
 
Sarcomas Research Line.
Bone and Soft tissue sarcomas includes a group of heterogeneous pathologies that were traditionally treated in the same way. The clinical investigation has allowed the identification of sub-groups with different response to treatments. The objective of this line of work is to find biomarkers for the best stratification of the patients, as well as to get a better knowledge of the molecular mechanisms for the development of these tumors.
 
Neuroendocrine tumors Research Line.
The neuroendocrine tumors (NET) include heterogeneous neoplasias, regarding morphologic and functionally features. They constitute a challenge for the medical management, mainly regarding diagnose and handling. Although we have improve the knowledge of molecular events related to their development in the last decade, we need to better known this tumors, in order to establish an early detection, that it improves the rates of survival.
 
In vitro 2- and 3D cell culture models for functional studies.
The identification of potential markers in different pathologies might be complemented by functional studies, focused on the characterization of cancer and estromal cell features, important for tumor development that it improves the rates of survival.
Research Lines
• Ovarian cancer
• Breast cancer
• Sarcomas
• Neuroendocrine tumors